M I Syed1, A Wolf2, O Ilan2, C O Hughes2, J Chung2, M Tymianski3, D D Pothier2, J A Rutka2. 1. TWJ fellow in Otology/Neurotology, University Health Network, Toronto, ON, Canada. 2. Otology/Neurotology, University Health Network, Toronto, ON, Canada. 3. Neurosurgery, University Health Network, Toronto, ON, Canada.
Abstract
OBJECTIVES: To evaluate the biological behaviour of tumour remnants intentionally left in the surgical bed following the incomplete excision of vestibular schwannomas (VS) and to review the relation between extent of resection and preservation of facial nerve function. METHODS: A retrospective chart review of 450 patients who underwent surgery for resection of VS over 23 years (1992-2014). Of these, 50 (11%) patients had residual tumour intentionally left on/around the facial nerve (near-total or subtotal excision) to preserve facial nerve function intra-operatively. The growth of residual tumour was evaluated using serial magnetic resonance imaging scanning; pre- and postoperative facial nerve function was assessed using the House-Brackmann grading scale. SETTING: Tertiary referral neurotology unit. RESULTS: Of the 42 non-NF2 cases where the tumour was intentionally incompletely excised, 28 (67%) patients underwent subtotal resection (mean follow-up 68.5 ± 39.0 months) and 14 (33%) underwent near-total resection (mean follow-up 72.9 ± 48.3 months). Three patients (all in subtotal resection group) showed regrowth. This was not statistically different from the near-total resection group (χ2 = 0.92, P = 0.31). The mean overall growth for these cases was 0.68 mm ± 0.32 mm/year. 5 (one near total, four subtotal) of the eight NF2 patients (62.5%) were excluded from our analysis. In the non-NF2 group, poor facial nerve outcomes (House-Brackmann scores of III-IV) were seen in 2/14 and V-VI in 3/14 of the near total compared with 7/25 and 4/25 respectively in the subtotal group. CONCLUSIONS: Given that the primary surgery for the VS was only for tumours that were relatively large or grew during conservative treatment, the low rate of tumour remnant growth (7%) is reassuring. It may be appropriate to have a lower threshold for leaving tumour on the facial nerve in non-NF2 patients where complete resection may jeopardise facial nerve function.
OBJECTIVES: To evaluate the biological behaviour of tumour remnants intentionally left in the surgical bed following the incomplete excision of vestibular schwannomas (VS) and to review the relation between extent of resection and preservation of facial nerve function. METHODS: A retrospective chart review of 450 patients who underwent surgery for resection of VS over 23 years (1992-2014). Of these, 50 (11%) patients had residual tumour intentionally left on/around the facial nerve (near-total or subtotal excision) to preserve facial nerve function intra-operatively. The growth of residual tumour was evaluated using serial magnetic resonance imaging scanning; pre- and postoperative facial nerve function was assessed using the House-Brackmann grading scale. SETTING: Tertiary referral neurotology unit. RESULTS: Of the 42 non-NF2 cases where the tumour was intentionally incompletely excised, 28 (67%) patients underwent subtotal resection (mean follow-up 68.5 ± 39.0 months) and 14 (33%) underwent near-total resection (mean follow-up 72.9 ± 48.3 months). Three patients (all in subtotal resection group) showed regrowth. This was not statistically different from the near-total resection group (χ2 = 0.92, P = 0.31). The mean overall growth for these cases was 0.68 mm ± 0.32 mm/year. 5 (one near total, four subtotal) of the eight NF2patients (62.5%) were excluded from our analysis. In the non-NF2 group, poor facial nerve outcomes (House-Brackmann scores of III-IV) were seen in 2/14 and V-VI in 3/14 of the near total compared with 7/25 and 4/25 respectively in the subtotal group. CONCLUSIONS: Given that the primary surgery for the VS was only for tumours that were relatively large or grew during conservative treatment, the low rate of tumour remnant growth (7%) is reassuring. It may be appropriate to have a lower threshold for leaving tumour on the facial nerve in non-NF2patients where complete resection may jeopardise facial nerve function.
Authors: Felix Arlt; Johannes Kasper; Dirk Winkler; Katja Jähne; Michael Karl Fehrenbach; Jürgen Meixensberger; Caroline Sander Journal: Front Neurol Date: 2022-05-24 Impact factor: 4.086
Authors: Ben A Strickland; Kristine Ravina; Robert C Rennert; Anna Jackanich; Ksenia Aaron; Joshua Bakhsheshian; Jonathan J Russin; Rick A Friedman; Steven L Giannotta Journal: J Neurol Surg B Skull Base Date: 2019-03-01
Authors: Hun Ho Park; So Hee Park; Hyeong-Cheol Oh; Hyun-Ho Jung; Jong Hee Chang; Kyu-Sung Lee; Won Seok Chang; Chang-Ki Hong Journal: Sci Rep Date: 2021-02-25 Impact factor: 4.379
Authors: Nick P de Boer; Radboud W Koot; Jeroen C Jansen; Stefan Böhringer; Jeroen A Crouzen; Andel G L van der Mey; Martijn J A Malessy; Erik F Hensen Journal: Otol Neurotol Date: 2021-03-01 Impact factor: 2.619
Authors: S K Plontke; P Caye-Thomasen; C Strauss; S Kösling; G Götze; U Siebolts; D Vordermark; L Wagner; L Fröhlich; T Rahne Journal: HNO Date: 2021-01 Impact factor: 1.284